CORONARY THROMBOLYSIS - STREPTOKINASE OR RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR

被引:119
作者
COLLEN, D [1 ]
机构
[1] UNIV VERMONT, COLL MED, BURLINGTON, VT 05405 USA
关键词
D O I
10.7326/0003-4819-112-7-529
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In patients with acute myocardial infarction, intravenous streptokinase therapy recanalizes 40% to 45% of occluded coronary arteries and reduces mortality by 25%. Recombinant tissue-type plasminogen activator (rt-PA) therapy is more potent for coronary arterial thrombolysis, producing both more rapid and more frequent (65% to 70%) reperfusion. Side effects (mainly reocclusion and bleeding) of streptokinase and rt-PA therapy are not markedly different. Whether the higher efficacy of rt-PA therapy will translate into a comparably larger reduction of morbidity and mortality remains to be determined in large comparative clinical trials. Both agents are available for clinical use. At present, the choice of agent for treating acute myocardial infarction must be based on consideration of the lower cost of streptokinase therapy compared with the established higher efficacy of rt-PA therapy for coronary recanalization.
引用
收藏
页码:529 / 538
页数:10
相关论文
共 70 条
[1]   RANDOMIZED COMPARISON OF INTRAVENOUS VERSUS INTRACORONARY STREPTOKINASE FOR MYOCARDIAL-INFARCTION [J].
ALDERMAN, EL ;
JUTZY, KR ;
BERTE, LE ;
MILLER, RG ;
FRIEDMAN, JP ;
CREGER, WP ;
ELIASTAM, M .
AMERICAN JOURNAL OF CARDIOLOGY, 1984, 54 (01) :14-19
[2]   MULTICENTER REPERFUSION TRIAL OF INTRAVENOUS ANISOYLATED PLASMINOGEN STREPTOKINASE ACTIVATOR COMPLEX (APSAC) IN ACUTE MYOCARDIAL-INFARCTION - CONTROLLED COMPARISON WITH INTRACORONARY STREPTOKINASE [J].
ANDERSON, JL ;
ROTHBARD, RL ;
HACKWORTHY, RA ;
SORENSEN, SG ;
FITZPATRICK, PG ;
DAHL, CF ;
HAGAN, AD ;
BROWNE, KF ;
SYMKOVIAK, GP ;
MENLOVE, RL ;
BARRY, WH ;
ECKERSON, HW ;
MARDER, VJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 11 (06) :1153-1163
[3]  
[Anonymous], 1988, LANCET, V2, P349
[4]  
BLEICH SD, 1989, CIRCULATION S2, V80, P113
[5]   MYOCARDIAL REPERFUSION, LIMITATION OF INFARCT SIZE, REDUCTION OF LEFT-VENTRICULAR DYSFUNCTION, AND IMPROVED SURVIVAL - SHOULD THE PARADIGM BE EXPANDED [J].
BRAUNWALD, E .
CIRCULATION, 1989, 79 (02) :441-444
[6]   UPDATE FROM THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION TRIAL [J].
BRAUNWALD, E ;
KNATTERUD, GL ;
PASSAMANI, E ;
ROBERTSON, TL ;
SOLOMON, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 10 (04) :970-970
[7]   INTRAVENOUS ANISOYLATED PLASMINOGEN STREPTOKINASE ACTIVATOR COMPLEX VERSUS INTRAVENOUS STREPTOKINASE IN EVOLVING MYOCARDIAL-INFARCTION - PRELIMINARY DATA FROM A RANDOMIZED MULTICENTER STUDY [J].
BROCHIER, ML ;
QUILLIET, L ;
KULBERTUS, H ;
MATERNE, P ;
LETAC, B ;
CRIBIER, A ;
MONASSIER, JP ;
SACREZ, A ;
FAVIER, JP .
DRUGS, 1987, 33 :140-145
[8]  
CHAMBERLAIN DA, 1988, LANCET, V1, P545
[9]  
CHESEBRO JH, 1988, NEW ENGL J MED, V319, P1544
[10]   THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) TRIAL, PHASE-I - A COMPARISON BETWEEN INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR AND INTRAVENOUS STREPTOKINASE - CLINICAL FINDINGS THROUGH HOSPITAL DISCHARGE [J].
CHESEBRO, JH ;
KNATTERUD, G ;
ROBERTS, R ;
BORER, J ;
COHEN, LS ;
DALEN, J ;
DODGE, HT ;
FRANCIS, CK ;
HILLIS, D ;
LUDBROOK, P ;
MARKIS, JE ;
MUELLER, H ;
PASSAMANI, ER ;
POWERS, ER ;
RAO, AK ;
ROBERTSON, T ;
ROSS, A ;
RYAN, TJ ;
SOBEL, BE ;
WILLERSON, J ;
WILLIAMS, DO ;
ZARET, BL ;
BRAUNWALD, E .
CIRCULATION, 1987, 76 (01) :142-154